Your Source for Venture Capital and Private Equity Financings

Parse Biosciences Secures $41.5M Series B

2022-02-15
SEATTLE, WA, Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, today announced $41.5 million in Series B funding.
The round was co-led by Marshall Wace and Janus Henderson Investors. Soleus Capital, Logos Capital and Bioeconomy Capital also participated in the round, bringing Parse Biosciences' total funding to date to over $50 million.

Parse Biosciences is a company with the mission of accelerating progress in human health and scientific research. At the core of the company is a pioneering approach for single cell sequencing. Single cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading